Not only are circadian agonists capable of inducing tumor cell death while producing no off-target (healthy cell) effects or toxicities, lethality has been observed in tumors depending upon upregulated signalers such as H-RAS, K-RAS, BRAF, PIK3CA, as well as in p53 null tumor cells [35]. This evidence concerns the gene HRAS and neoplasm.